Person:
ÇAM, MUHAMMET EMİN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÇAM

First Name

MUHAMMET EMİN

Name

Filters

2020 - 20212
Reset filters

Settings

Author: AKAKIN, DİLEK × Subject: DELIVERY ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Evaluation of burst release and sustained release of pioglitazone-loaded fibrous mats on diabetic wound healing: an in vitro and in vivo comparison study
    (ROYAL SOC, 2020-01) AKAKIN, DİLEK; Cam, Muhammet Emin; Yildiz, Sila; Alenezi, Hussain; Cesur, Sumeyye; Ozcan, Gul Sinemcan; Erdemir, Gokce; Edirisinghe, Ursula; Akakin, Dilek; Kuruca, Durdane Serap; Kabasakal, Levent; Gunduz, Oguzhan; Edirisinghe, Mohan
    In order to provide more effective treatment strategies for the rapid healing of diabetic wounds, novel therapeutic approaches need to be developed. The therapeutic potential of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist pioglitazone hydrochloride (PHR) in two different release kinetic scenarios, burst release and sustained release, was investigated and compared with in vitro and in vivo tests as potential wound healing dressings. PHR-loaded fibrous mats were successfully fabricated using polyvinyl-pyrrolidone and polycaprolactone by scalable pressurized gyration. The results indicated that PHR-loaded fibrous mats expedited diabetic wound healing in type-1 diabetic rats and did not show any cytotoxic effect on NIH/3T3 (mouse embryo fibroblast) cells, albeit with different release kinetics and efficacies. The wound healing effects of fibrous mats are presented with histological and biochemical evaluations. PHR-loaded fibrous mats improved neutrophil infiltration, oedema, and inflammation and increased epidermal regeneration and fibroblast proliferation, but the formation of hair follicles and completely improved oedema were observed only in the sustained release form. Thus, topical administration of PPAR-gamma agonist in sustained release form has high potential for the treatment of diabetic wounds in inflammatory and proliferative phases of healing with high bioavailability and fewer systemic side effects.
  • Thumbnail Image
    PublicationOpen Access
    Accelerated diabetic wound healing by topical application of combination oral antidiabetic agents-loaded nanofibrous scaffolds: An in vitro and in vivo evaluation study
    (ELSEVIER, 2021-02) YAVUZ, AYŞE NUR; Cam, Muhammet Emin; Ertas, Busra; Alenezi, Hussain; Hazar-Yavuz, Ayse Nur; Cesur, Sumeyye; Ozcan, Gul Sinemcan; Ekentok, Ceyda; Guler, Ece; Katsakouli, Christina; Demirbas, Zehra; Akakin, Dilek; Eroglu, Mehmet Sayip; Kabasakal, Levent; Gunduz, Oguzhan; Edirisinghe, Mohan
    The combination of oral antidiabetic drugs, pioglitazone, metformin, and glibenclamide, which also exhibit the strongest anti-inflammatory action among oral antidiabetic drugs, were loaded into chitosan/gelatin/polycaprolactone (PCL) by electrospinning and polyvinyl pyrrolidone (PVP)/PCL composite nanofibrous scaffolds by pressurized gyration to compare the diabetic wound healing effect. The combination therapies significantly accelerated diabetic wound healing in type-1 diabetic rats and organized densely packed collagen fibers in the dermis, it also showed better regeneration of the dermis and epidermis than single drug-loaded scaffolds with less inflammatory cell infiltration and edema. The formation of the hair follicles started in 14 days only in the combination therapy and lower proinflammatory cytokine levels were observed compared to single drug-loaded treatment groups. The combination therapy increased the wettability and hydrophilicity of scaffolds, demonstrated sustained drug release over 14 days, has high tensile strength and suitable cytocompatibility on L929 (mouse fibroblast) cell and created a suitable area for the proliferation of fibroblast cells. Consequently, the application of metformin and pioglitazone-loaded chitosan/gelatin/PCL nanofibrous scaffolds to a diabetic wound area offer high bioavailability, fewer systemic side effects, and reduced frequency of dosage and amount of drug.